-
Report details
-
54
Figures
-
49
Tables
-
Chapter 1: Executive Summary
-
Introduction
-
$40.2 Billion in Funding During 2022
-
Quarterly Funding Amounts
-
Quarterly Funding Category Shares, Q1 2021 Through Q1 2023
-
Quarterly Deal Counts by Category, Q1 2021 – Q1 2023
-
Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribut…
-
A Look at Less Frequent CGT Deal Types
-
Synopsis of Most Active Deal-Making Companies
-
Chapter 2: Venture Capital & Private Funding
-
VC/Private Funding in Flux
-
Chapter 3: Strategic Investments
-
Strategic Investments in Cell and Gene Therapy
-
Most Active Companies
-
Chapter 4: IPOs, FPOs, & SPACs
-
North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
-
Chapter 5: Mergers & Acquisitions (M&A)
-
Growing Numbers of M&A, Despite Lower Average Value
-
Most Active Companies
-
Chapter 6: Technology/Research/Strategic Collaborations
-
CGT Market Sees a Broad Variety of Collaborations
-
Most Active Companies
-
Chapter 7: Licensing
-
Stable Levels of Licensing in the Cell and Gene Therapy Market
-
Most Active Companies
-
Chapter 8: Manufacturing and Supply Chain
-
Major Growth in Manufacturing and Supply Chain Management Activity in CGT
-
Most Active Companies
-
Chapter 9: Public Outreach, Education, & Philanthropy
-
CGT Market Focusing Less on Public Outreach, Patient/ Consumer/ Trainee Educatio…
-
Chapter 10: Distribution & Co-Marketing
-
A Look at CGT Distribution and Co-Marketing Deals
-
Most Active Companies
-
Chapter 11: Other – JV, Restructuring, Termination, Spinoffs
-
A Look at Other Types of Deals Impacting Cell and Gene Therapy
-
Chapter 12: Other – New Facilities, Expansion; Real Estate
-
Expansion, New Facilities and Related Announcements
-
Appendix: Cell and Gene Therapy Market Assessment
-
Market Outlook, 2022-2032
-
Regional Market
-
Products on the Market
-
Top Companies in Cell and Gene Therapy
|
Cell and Gene Therapy Market and Deals Analysis, 2023: Financings, Partnering, Mergers and Acquisitions, Tech Transfers, IPOs, and Other Deals
22 May 2023
This report, Kalorama's Cell and Gene Deals and Market Analysis, tracks the dealmaking and market opportunity for cell and gene therapy companies. A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. Kalorama's latest report finds that the volume of deals between companies and other funding entities involving CGT is up, and companies have continued to receive large amounts of investment despite a decline from 2021 levels of investment.
Kalorama's CGT deals amounted to a staggering $40 billion in 2022.
While the concepts of gene therapy and cell therapy have been investigated for decades, there were major challenges in the early years. Through incremental progress, and the gradual introduction of enabling tools such as CRISPR and next-generation sequencing (NGS), cell and gene therapy has emerged into a highly active area. There are now many approved therapies with proven track records.
As the new tools have lowered the barriers to entry for the industry, over 1,500 companies have been created or have become involved.
The following is just some of the information in this report:
- Most Active Deal-Making Companies
- Deals per Month, April 2021-March 2023
- Deals by Type - Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation
- Venture Capital and Private Funding Deals by Month, January 2021-March 2023 (Total count)
- Regional Venture Capital/Private Funding Shares [North America, Europe, APAC, Rest of World] (%)
- Total Number of Mergers and Acquisitions, By Month
- Average Merger/Acquisition Amount, By Quarter [Q1 2021-Q1 2023] ($M)
- List of M&As [Company 1, Company 2, Details, Amount, w/Milestones, Date]
- Most Frequent Types of Deals, by Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (Total number)
- Most Active Companies in Acquisition/Merger/ Strategic Investment
- Most Active Companies in Overall Deals, Collaborations
- Estimated Market Forecasts for Cell and Gene Therapies by Type (Gene Therapy, Cell Therapy)
- Estimated Market Forecasts by Region (North America, EU, APAC, Other)
- Estimated Market Forecasts for CGT by Disease Category (Oncology, Other)
No report published by a major market research publisher has tackled the Cell and Gene Therapy dealmaking space as it exists in 2023 in a more comprehensive fashion. As Cell and Gene Therapy is a highly competitive marketplace, hundreds of companies are referenced in this report.
Page Count: 261
Table of Contents
-
Chapter 1: Executive Summary
-
Introduction
-
$40.2 Billion in Funding During 2022
-
Quarterly Funding Amounts
-
Quarterly Funding Category Shares, Q1 2021 Through Q1 2023
-
Quarterly Deal Counts by Category, Q1 2021 – Q1 2023
-
Growth in Collaborations, Manufacturing/Supply Chain Deals, Licensing, Distribution/ Co-Marketing Highlight Activity in Cell and Gene Therapy
-
A Look at Less Frequent CGT Deal Types
-
Synopsis of Most Active Deal-Making Companies
-
Chapter 2: Venture Capital & Private Funding
-
VC/Private Funding in Flux
-
Chapter 3: Strategic Investments
-
Strategic Investments in Cell and Gene Therapy
-
Most Active Companies
-
Chapter 4: IPOs, FPOs, & SPACs
-
North America Sees the Majority of Proceeds from IPOs, FPOs, SPACs
-
Chapter 5: Mergers & Acquisitions (M&A)
-
Growing Numbers of M&A, Despite Lower Average Value
-
Most Active Companies
-
Chapter 6: Technology/Research/Strategic Collaborations
-
CGT Market Sees a Broad Variety of Collaborations
-
Most Active Companies
-
Chapter 7: Licensing
-
Stable Levels of Licensing in the Cell and Gene Therapy Market
-
Most Active Companies
-
Chapter 8: Manufacturing and Supply Chain
-
Major Growth in Manufacturing and Supply Chain Management Activity in CGT
-
Most Active Companies
-
Chapter 9: Public Outreach, Education, & Philanthropy
-
CGT Market Focusing Less on Public Outreach, Patient/ Consumer/ Trainee Education, and Philanthropy
-
Chapter 10: Distribution & Co-Marketing
-
A Look at CGT Distribution and Co-Marketing Deals
-
Most Active Companies
-
Chapter 11: Other – JV, Restructuring, Termination, Spinoffs
-
A Look at Other Types of Deals Impacting Cell and Gene Therapy
-
Chapter 12: Other – New Facilities, Expansion; Real Estate
-
Expansion, New Facilities and Related Announcements
-
Appendix: Cell and Gene Therapy Market Assessment
-
Market Outlook, 2022-2032
-
Regional Market
-
Products on the Market
-
Top Companies in Cell and Gene Therapy
|
More information about this product
Other Users Also Viewed
18 May 2023
Clinical Laboratory Services Market, 8th Edition provides an overview of the clinical laboratory industry and the trends driving growth.
Included in the report are statistics influencing the industry, incidence of diseases in the U.S. and worldwid…
|